Head and Neck Cancer Clinical Trial
Official title:
Phase I Evaluation of Erlotinib and Docetaxel With Concomitant Boost Radiation for Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck
The goal of this clinical research study is to find the highest safe dose of the drugs OSI-774 and docetaxel that can be given together along with radiation treatment for advanced head and neck cancer.
OSI-774 (also known as Erlotinib or Tarceva) is a drug that helps to block the activity of
an enzyme that is believed to play an important role in cell growth. It is hoped that
blocking this enzyme will slow tumor growth. Docetaxel (Taxotere) is a commonly used
chemotherapy drug. Docetaxel is designed to target and destroy cancer cells.
Before beginning treatment, you will have a complete physical exam. You will also have
routine blood (about 4 teaspoons) and urine tests, a chest x-ray or CT scan, and an
electrocardiogram (ECG - test to measure the electrical activity of the heart). You will
have a dental exam performed by a dentist. Women who are able to have children must have a
negative pregnancy test (blood or urine). You will also have either a CT scan or a MRI to
measure your disease. You may have a bone scan and/or CT scans of your abdomen and chest if
your doctor thinks it is necessary for your care.
You will have a swallowing evaluation. The swallowing evaluation involves drinking barium
and other liquids of varying thickness while fluoroscopy (like an x-ray movie) is done to
evaluate swallowing function. You will also complete a questionnaire that asks questions
about quality of life issues. The questionnaire should take about 10 minutes to complete.
In this study you will receive radiation therapy 5 days per week (Monday through Friday) for
6 weeks. You will not receive radiation therapy on weekends. For the first 3 weeks of
treatment you will receive radiation once a day. Starting on the 4th week of treatment, you
will receive radiation treatment twice a day. The treatments will be at least 6 hours apart.
You will receive these twice daily radiation treatments Monday through Friday for 3 weeks.
On your first day of radiation treatment you will also receive your first dose of docetaxel.
You will receive docetaxel by vein over 15 to 30 minutes on Days 1, 8, 15, and 22 of
treatment.
Beginning on Day 2 of treatment, you will begin taking OSI-774 by mouth. You will take
OSI-774 once a day in the morning with up to 7 ounces of water either 2 hours after or 1
hour before eating. If you are unable to swallow the OSI-774, you may dissolve it in
distilled water and take it through a feeding tube. You will take OSI-774 every day while on
treatment except on days on which you receive docetaxel (i.e., Days 1, 8, 15, and 22). You
should not take OSI-774 on days you receive a docetaxel infusion.
Participants will enter this study in groups of 3. The doses of both OSI-774 and docetaxel
will be increased after each group. Six patients will be studied at the dose level that is
estimated to be the highest safe dose.
While receiving treatment on this study, you will be examined at least once a week. You will
also have weekly blood tests (2-4 teaspoons). At the end of treatment, you will have another
CT scan or MRI to measure your disease. You will also have a complete physical exam and
blood tests (4 teaspoons). You may be taken off study if your disease gets worse or
intolerable side effects occur.
After completing treatment, you will have a follow-up visit every 3 months for 2 years, then
every 4 months during Year 3, and every 6 months during Years 4 and 5. These visits will
include a medical history and physical exam. A CT or MRI study and blood work (2-4
teaspoons) may also be done. You will have swallowing evaluations at 3 and 12 months
following treatment, and then once yearly through year 5. When you have these swallowing
evaluations, you will also be asked to complete a short questionnaire about swallowing. The
questionnaire will take about 10 minutes to complete.
This is an investigational study. OSI-774 is approved by the FDA for treatment of non-small
cell lung cancer. Docetaxel is approved by the FDA for treatment of lung cancer and breast
cancer. Their use together in this study with radiation treatment is experimental. Up to 24
patients are expected to take part in this study. All will be enrolled at M. D. Anderson.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05808920 -
The RESCUE Study: Survival and Functional Outcomes Following Salvage Surgery for RESidual or reCurrent sqUamous cEll Carcinoma of the Head and Neck
|
||
| Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
| Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03997643 -
Preservation of Swallowing in Respected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects (PRESERVE): A Randomized Trial
|
Phase 2 | |
| Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04700475 -
Effect of Low Level Laser Therapy on Prevention of Radiotherapy Induced Xerostomia in Cancer Patients.
|
N/A | |
| Withdrawn |
NCT04058145 -
AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
| Completed |
NCT02572869 -
Functional and Aesthetic Outcomes After Mandible Reconstruction With Fibula Osteomyocutaneous Free Flaps
|
||
| Active, not recruiting |
NCT04474470 -
A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT05073809 -
Photoacoustic Imaging of Head and Neck Tumours
|
||
| Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
| Active, not recruiting |
NCT03651570 -
Randomized Controlled Trial of a E-intervention to Help Patients Newly Diagnosed With Cancer Cope Better: Pilot Study
|
N/A | |
| Recruiting |
NCT04930432 -
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06016699 -
Immunological Function After Radiation With Either Proton or Photon Therapy
|
||
| Terminated |
NCT03843554 -
Commensal Oral Microbiota in Head and Neck Cancer
|
N/A | |
| Recruiting |
NCT05915572 -
Mulligan Technique on Shoulder Dysfunction
|
N/A | |
| Completed |
NCT05897983 -
Tens and Rocabado Exercises on TMJ Dysfunction
|
N/A | |
| Not yet recruiting |
NCT06289049 -
Heavy Strength Training in Head and Neck Cancer Survivors
|
Phase 2 | |
| Withdrawn |
NCT05263648 -
Virtual Reality Software to Reduce Stress in Cancer Patients
|
N/A | |
| Withdrawn |
NCT03238638 -
A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy
|
Phase 2 |